-
Something wrong with this record ?
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma
J. Bedke, L. Albiges, U. Capitanio, RH. Giles, M. Hora, TB. Lam, B. Ljungberg, L. Marconi, T. Klatte, A. Volpe, Y. Abu-Ghanem, S. Dabestani, S. Fernández-Pello, F. Hofmann, T. Kuusk, R. Tahbaz, T. Powles, A. Bex
Language English Country Switzerland
Document type Journal Article
- MeSH
- Anilides therapeutic use MeSH
- Axitinib MeSH
- Immune Checkpoint Inhibitors MeSH
- Ipilimumab therapeutic use MeSH
- Carcinoma, Renal Cell * drug therapy MeSH
- Humans MeSH
- Kidney Neoplasms * drug therapy MeSH
- Nivolumab therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Pyridines therapeutic use MeSH
- Sunitinib therapeutic use MeSH
- Urology * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. PATIENT SUMMARY: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.
Academic Urology Unit University of Aberdeen Aberdeen UK
Department of Cancer Medicine Gustave Roussy Université Paris Saclay Villejuif France
Department of Nephrology and Hypertension University Medical Center Utrecht Utrecht The Netherlands
Department of Surgery University of Cambridge Cambridge UK
Department of Surgical and Perioperative Sciences Urology and Andrology Umeå University Umeå Sweden
Department of Translational Medicine Division of Urological Cancers Lund University Malmö Sweden
Department of Urology Aberdeen Royal Infirmary Aberdeen UK
Department of Urology Cabueñes University Hospital Gijón Spain
Department of Urology Chaim Sheba Medical Center Tel Hashomer Ramat Gan Israel
Department of Urology Coimbra University Hospital Coimbra Portugal
Department of Urology Darent Valley Hospital Dartford and Gravesham NHS Trust Dartford UK
Department of Urology Elbe Kliniken Stade Germany
Department of Urology Royal Bournemouth Hospital Bournemouth UK
Department of Urology San Raffaele Scientific Institute Milan Italy
Department of Urology Sunderby Sjukhus Umeå University Luleå Sweden
Department of Urology University Hospital Tuebingen Tuebingen Germany
Department of Urology University of Eastern Piedmont Maggiore della Carità Hospital Novara Italy
German Cancer Consortium Heidelberg Germany
Patient Advocate International Kidney Cancer Coalition Utrecht The Netherlands
The Royal Free London NHS Foundation Trust London UK
The Royal Free NHS Trust and Barts Cancer Institute Queen Mary University of London London UK
UCL Division of Surgery and Interventional Science University College London London UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012515
- 003
- CZ-PrNML
- 005
- 20220506125903.0
- 007
- ta
- 008
- 220425s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2020.12.005 $2 doi
- 035 __
- $a (PubMed)33357997
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Bedke, Jens $u Department of Urology, University Hospital Tuebingen, Tuebingen, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
- 245 10
- $a Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma / $c J. Bedke, L. Albiges, U. Capitanio, RH. Giles, M. Hora, TB. Lam, B. Ljungberg, L. Marconi, T. Klatte, A. Volpe, Y. Abu-Ghanem, S. Dabestani, S. Fernández-Pello, F. Hofmann, T. Kuusk, R. Tahbaz, T. Powles, A. Bex
- 520 9_
- $a Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. PATIENT SUMMARY: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.
- 650 _2
- $a anilidy $x terapeutické užití $7 D000813
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a axitinib $7 D000077784
- 650 12
- $a karcinom z renálních buněk $x farmakoterapie $7 D002292
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibitory kontrolních bodů $7 D000082082
- 650 _2
- $a ipilimumab $x terapeutické užití $7 D000074324
- 650 12
- $a nádory ledvin $x farmakoterapie $7 D007680
- 650 _2
- $a nivolumab $x terapeutické užití $7 D000077594
- 650 _2
- $a pyridiny $x terapeutické užití $7 D011725
- 650 _2
- $a sunitinib $x terapeutické užití $7 D000077210
- 650 12
- $a urologie $7 D014572
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Albiges, Laurence $u Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- 700 1_
- $a Capitanio, Umberto $u Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy
- 700 1_
- $a Giles, Rachel H $u Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands; Patient Advocate, International Kidney Cancer Coalition, Utrecht, The Netherlands
- 700 1_
- $a Hora, Milan $u Department of Urology, University Hospital Pilsen and Charles University Faculty of Medicine in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Lam, Thomas B $u Academic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK
- 700 1_
- $a Ljungberg, Börje $u Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
- 700 1_
- $a Marconi, Lorenzo $u Department of Urology, Coimbra University Hospital, Coimbra, Portugal
- 700 1_
- $a Klatte, Tobias $u Department of Urology, Royal Bournemouth Hospital, Bournemouth, UK; Department of Surgery, University of Cambridge, Cambridge, UK
- 700 1_
- $a Volpe, Alessandro $u Department of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy
- 700 1_
- $a Abu-Ghanem, Yasmin $u Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
- 700 1_
- $a Dabestani, Saeed $u Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden
- 700 1_
- $a Fernández-Pello, Sergio $u Department of Urology, Cabueñes University Hospital, Gijón, Spain
- 700 1_
- $a Hofmann, Fabian $u Department of Urology, Sunderby Sjukhus, Umeå University, Luleå, Sweden
- 700 1_
- $a Kuusk, Teele $u Department of Urology, Darent Valley Hospital, Dartford and Gravesham NHS Trust, Dartford, UK
- 700 1_
- $a Tahbaz, Rana $u Department of Urology, Elbe Kliniken, Stade, Germany
- 700 1_
- $a Powles, Thomas $u The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK
- 700 1_
- $a Bex, Axel $u The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: a.bex@ucl.ac.uk
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 79, č. 3 (2021), s. 339-342
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33357997 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125856 $b ABA008
- 999 __
- $a ok $b bmc $g 1789920 $s 1163716
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 79 $c 3 $d 339-342 $e 20201224 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20220425
